Monday - December 23, 2024
American Society of Hematology: Stem Cell Transplant Offers No Additional Benefit for Patients With Mantle Cell Lymphoma in Deep Remission
December 11, 2024
WASHINGTON, Dec. 11 (TNSres) -- The American Society of Hematology issued the following news release:

* * *

Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone

LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-A . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products